🟢 Solid Biosciences is trading 6.08% up today in pre-market after RBC initiated coverage with Outperform rating

Solid Biosciences is trading at $9.25, up 6.08% in pre-market after RBC Capital Markets initiated coverage with an Outperform rating.

• The firm initiated coverage on September 16 with an $18 price target.
• RBC highlighted potential for SGT-003, Solid Biosciences’ Duchenne muscular dystrophy gene-therapy candidate.
• Major U.S. indices are up more than 0.5% pre-market, supporting broader risk sentiment.